Raymond James Financial
CMPX icon

Raymond James Financial’s Compass Therapeutics CMPX Stock Holding History

Raymond James Financial’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-121,889
Closed -$645K – 5427
2026
Q1 		$645K Buy
121,889
+41,747
+52% +$241K ﹤0.01% 4178
2025
Q4 		$430K Buy
+80,142
New +$370K ﹤0.01% 4366
2025
Q3 		– Sell
-4,894
Closed -$12.7K – 5313
2025
Q2 		$12.7K Buy
+4,894
New +$10.1K ﹤0.01% 5815

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Raymond James Financial's CMPX Position: Q2 2026 in Review

Raymond James Financial sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 121,889 shares — an estimated $645K sold.

Raymond James Financial first reported a position in CMPX in Q2 2025 and held it in 3 quarters. The position peaked at $645K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Raymond James Financial reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 121,889 Compass Therapeutics shares in Q2 2026, an estimated $645K.
  • Raymond James Financial first reported a position in Compass Therapeutics in Q2 2025 and held it in 3 quarters.
  • Raymond James Financial's Compass Therapeutics position peaked at $645K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.